EGFR and neoplasm: Further investigation suggested that low-fractionated EGFR-TKIs (HypoTKI) were more effective than standard hyperfractionated EGFR-TKIs (HyperTKI) because HypoTKI can induce more dsDNA and RNA release than HyperTKI in vivo and trigger MyD88–type I IFN innate sensing pathways, which enhance tumor-specific T-cell infiltration and reactivation.